Caterina Branca

Caterina Branca, Ph.D.

Research Assistant Professor

Department: Pharmacodynamics
Business Phone: (352) 273-7700
Business Email: caterina.branca@ufl.edu

About Caterina Branca

Caterina Branca obtained her Ph.D. in Neuroscience from the University of Brescia – School of Medicine, Italy. During her early academic career, she focused on dissecting the molecular mechanisms underlying neurodegenerative diseases, particularly Alzheimer’s disease, using animal models and conducting comprehensive biochemical and molecular analyses. Her primary projects explored programmed cell death pathways, which play a crucial role in neuronal loss across neurodegenerative conditions. This experience provided her with a foundation to develop and implement innovative approaches in neuroscience research.

After time in academia, she transitioned to private industry as a Field Application Scientist, gaining valuable insights into applied research and its translation to practical applications. However, she ultimately felt drawn back to the challenges and dynamic environment of basic research, leading her to return to academia.

Currently, as a Research Assistant Professor in Dr. Marco Bortolato’s lab, her work focuses on neurodevelopmental disorders, with an emphasis on Tic disorders. Her research aims to uncover the underlying biological mechanisms that drive these conditions, with the long-term goal of identifying novel therapeutic targets and developing strategies that could lead to effective treatments. In this role, she is dedicated to advancing the understanding of neurodevelopmental diseases, bridging fundamental research with potential clinical applications to address pressing unmet needs in the field.

Publications

Academic Articles
2025
Prefrontal 5α-reductase 2 mediates male-specific acute stress response
Science Advances. 11(4) [DOI] 10.1126/sciadv.adr0563. [PMID] 39841836.
2024
Activation of M4 muscarinic receptors in the striatum reduces tic-like behaviours in two distinct murine models of Tourette syndrome.
British journal of pharmacology. 181(17):3064-3081 [DOI] 10.1111/bph.16392. [PMID] 38689378.
2024
Exploring persistence in animal models: The sinking platform test.
Journal of neuroscience methods. 415 [DOI] 10.1016/j.jneumeth.2024.110352. [PMID] 39681208.
2024
The role of neuroactive steroids in tic disorders.
Neuroscience and biobehavioral reviews. 160 [DOI] 10.1016/j.neubiorev.2024.105637. [PMID] 38519023.
2023
Elevated RIPK3 correlates with disease burden in myelofibrosis.
Blood advances. 7(7):1219-1224 [DOI] 10.1182/bloodadvances.2021006838. [PMID] 36453650.
2023
High RIPK3 expression is associated with a higher risk of early kidney transplant failure.
iScience. 26(10) [DOI] 10.1016/j.isci.2023.107879. [PMID] 37868627.
2022
Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
Journal of cancer research and clinical oncology. 148(2):331-340 [DOI] 10.1007/s00432-021-03827-9. [PMID] 34654952.
2022
The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner.
Oncogene. 41(9):1376-1382 [DOI] 10.1038/s41388-021-02161-1. [PMID] 35091677.
2021
XIAP restrains TNF-driven intestinal inflammation and dysbiosis by promoting innate immune responses of Paneth and dendritic cells.
Science immunology. 6(65) [DOI] 10.1126/sciimmunol.abf7235. [PMID] 34739338.
2020
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically.
Nature communications. 11(1) [DOI] 10.1038/s41467-020-18372-1. [PMID] 32913197.
2019
Temporal and regional progression of Alzheimer’s disease-like pathology in 3xTg-AD mice.
Aging cell. 18(1) [DOI] 10.1111/acel.12873. [PMID] 30488653.
2018
Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits.
Aging cell. 17(4) [DOI] 10.1111/acel.12775. [PMID] 29749079.
2017
Dyrk1 inhibition improves Alzheimer’s disease-like pathology.
Aging cell. 16(5):1146-1154 [DOI] 10.1111/acel.12648. [PMID] 28779511.
2017
Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer’s disease.
Human molecular genetics. 26(24):4823-4835 [DOI] 10.1093/hmg/ddx361. [PMID] 29036636.
2017
Necroptosis activation in Alzheimer’s disease.
Nature neuroscience. 20(9):1236-1246 [DOI] 10.1038/nn.4608. [PMID] 28758999.
2017
Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation.
International journal of molecular sciences. 18(1) [DOI] 10.3390/ijms18010184. [PMID] 28106772.
2017
Paving the Way for New Clinical Trials for Alzheimer’s Disease.
Biological psychiatry. 81(2):88-89 [DOI] 10.1016/j.biopsych.2016.10.016. [PMID] 27938878.
2015
CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.
Neuroscience. 302:112-20 [DOI] 10.1016/j.neuroscience.2014.10.029. [PMID] 25450955.
2015
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Journal of the National Cancer Institute. 107(5) [DOI] 10.1093/jnci/djv041. [PMID] 25739547.
2015
NF-κB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases.
Frontiers in neurology. 6 [DOI] 10.3389/fneur.2015.00098. [PMID] 26042083.
2015
Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer’s Disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 35(41):14042-56 [DOI] 10.1523/JNEUROSCI.2781-15.2015. [PMID] 26468204.
2014
Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer’s disease.
Neurobiology of aging. 35(12):2726-2735 [DOI] 10.1016/j.neurobiolaging.2014.06.011. [PMID] 25034342.
2014
Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 34(23):7988-98 [DOI] 10.1523/JNEUROSCI.0777-14.2014. [PMID] 24899720.
2014
Pharmacological targeting of the β-amyloid precursor protein intracellular domain.
Scientific reports. 4 [DOI] 10.1038/srep04618. [PMID] 24714650.
2013
Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window.
Neurobiology of disease. 49:177-89 [DOI] 10.1016/j.nbd.2012.08.018. [PMID] 22971966.
2012
Glutamatergic neurons induce expression of functional glutamatergic synapses in primary myotubes.
PloS one. 7(2) [DOI] 10.1371/journal.pone.0031451. [PMID] 22347480.
2012
NF-κB and epigenetic mechanisms as integrative regulators of brain resilience to anoxic stress.
Brain research. 1476:203-10 [DOI] 10.1016/j.brainres.2012.04.013. [PMID] 22575713.
2011
The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer’s disease.
Journal of molecular neuroscience : MN. 45(1):22-31 [DOI] 10.1007/s12031-010-9482-2. [PMID] 21181298.
2010
The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury.
Cell death & disease. 1(11) [DOI] 10.1038/cddis.2010.76. [PMID] 21368872.

Contact Details

Phones:
Business:
(352) 273-7700
Emails:
Addresses:
Business Mailing:
1345 CENTER DR
GAINESVILLE FL 32610
Business Street:
1345 CENTER DR RM P1 # 32
GAINESVILLE UT 32610